Official websites use. Share sensitive information only on official, secure websites. Brouwer 1 ; D. Ellis 2 ; A. Antanasijevic 3 ; A. Yasmeen 4 ; Z. Berndsen 3 ; T. Bijl 1 ; J. Burger 1 ; B. Nickerson 2 ; C. Cottrell 3 ; J. Allen 5 ; I. Bontjer 1 ; M. Crispin 5 ; D. Baker 2 ; A. Ward 3 ; J. Moore 4 ; P. Klasse 4 ; N. King 2 and R. Sanders 1. The protruding SOSIP trimers maintain their antigenic integrity as observed by surface plasmon resonance and, in contrast to their soluble counterparts, induce strong activation of cognate B cells in vitro.
This may provide a considerable advantage over particles that are assembled intracellularly i. Madani 1 ; A. Princiotto 2 ; L. Mach 3 ; J. Richard 4 ; B. Hora 5 ; C. Zhao 6 ; T. Bradley 7 ; B. Melillo 8 ; A. Finzi 9 ; B. Haynes 10 ; A. Smith 8 ; S. Santra 11 ; J. Moss 12 ; M. Baum 12 and J. Sodroski 2. Three groups of monkeys were used in the present study. The protective immune response persists for at least six months after vaccination. Jones 1 ; R. Wyatt 3 ; C. LaBranche 4 ; X.
Shen 5 ; G. Tomaras 5 ; D. Montefiori 5 ; B. Moss 3 ; J. Clements 6 ; D. Barouch 7 ; P. Kozlowski 8 ; R. Varadarajan 2 and R. Amara 1. Here we evaluate the immunogenicity and efficacy of oral vaccination and compare it with systemic vaccinations in rhesus macaques RM.
All animals were challenged intrarectally at around five months after the final immunization with a pathogenic SHIVP3 for a maximum of six challenges. They also show that MVA prime followed by a gp trimer boost can provide a significant protection against intrarectal SHIV challenges. Tomaka 1 ; D. Stieh 2 ; D. Barouch 3 ; M. Robb 4,5 ; N. Michael 4 ; G. Tomaras 6 ; G. Alter 7 ; J. McElrath 8 ; L. Lavreys 9 ; S. Nijs 9 ; K. Callewaert 2 ; J.
Hendriks 2 ; Z. Euler 2 ; M. Pau 2 and H. Schuitemaker 2. Background: Globally, 1. Week 28 and 52 data showed Ad HIV double prime, and Ad We here present data on durability of immune responses. Methods: Healthy, uninfected participants were randomized into seven vaccine regimens, or a placebo and administered Ad HIV double prime Weeks 0 and 12 and a double boost of either Ad Groups boosted with Ad Conclusions: All participants in Ad HIV prime with Ad Stephenson 1,2 ; J. Ansel 1 ; S. Walsh 1 ; C.
